stoxline Quote Chart Rank Option Currency Glossary
  
DexCom, Inc. (DXCM)
85.33  1.96 (2.35%)    07-14 16:00
Open: 83.42
High: 85.6
Volume: 2,364,577
  
Pre. Close: 83.37
Low: 83.16
Market Cap: 33,458(M)
Technical analysis
2025-07-14 4:39:38 PM
Short term     
Mid term     
Targets 6-month :  103.15 1-year :  120.48
Resists First :  88.31 Second :  103.15
Pivot price 84.43
Supports First :  81.82 Second :  77.8
MAs MA(5) :  84.55 MA(20) :  83.72
MA(100) :  78.78 MA(250) :  77.88
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  65.7 D(3) :  65.1
RSI RSI(14): 54.1
52-week High :  117.19 Low :  57.52
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DXCM ] has closed below upper band by 38.1%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 85.7 - 86.04 86.04 - 86.33
Low: 82.23 - 82.64 82.64 - 83
Close: 84.6 - 85.29 85.29 - 85.88
Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Headline News

Mon, 14 Jul 2025
When Should You Buy DexCom, Inc. (NASDAQ:DXCM)? - 富途牛牛

Wed, 09 Jul 2025
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire

Mon, 07 Jul 2025
What You Need to Know Ahead of DexCom’s Earnings Release - Yahoo Finance

Tue, 01 Jul 2025
Dexcom Sets Q2 2025 Earnings Date: Key Details for July 30 Conference Call - Stock Titan

Tue, 24 Jun 2025
Abbott stock DexCom stock gain on RFK Jr. comments (DXCM) - Seeking Alpha

Mon, 02 Jun 2025
Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 392 (M)
Shares Float 389 (M)
Held by Insiders 0.4 (%)
Held by Institutions 97 (%)
Shares Short 9,380 (K)
Shares Short P.Month 11,280 (K)
Stock Financials
EPS 1.33
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.78
Profit Margin 12.8 %
Operating Margin 12.9 %
Return on Assets (ttm) 5.9 %
Return on Equity (ttm) 23.7 %
Qtrly Rev. Growth 12.5 %
Gross Profit (p.s.) 6.29
Sales Per Share 10.58
EBITDA (p.s.) 2.18
Qtrly Earnings Growth -25.8 %
Operating Cash Flow 964 (M)
Levered Free Cash Flow 509 (M)
Stock Valuations
PE Ratio 64.15
PEG Ratio 0
Price to Book value 14.76
Price to Sales 8.06
Price to Cash Flow 34.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android